Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TONDRE TREMAINE BUCK

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1003027764
CMS profile
181514
Location
SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$69,512.79

177 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $65,092.92 16
Food and Beverage $3,504.45 156
Travel and Lodging $712.83 2
Education $202.59 3

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TONDRE TREMAINE BUCK

NPI 1003027764 · CMS profile ID 181514

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003027764?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TONDRE TREMAINE BUCK, NPI 1003027764, CMS profile ID 181514. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003027764?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). TONDRE TREMAINE BUCK, NPI 1003027764, CMS profile ID 181514. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003027764?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
TONDRE TREMAINE BUCK, NPI 1003027764, CMS profile ID 181514, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1003027764?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

177 matching records · $69,512.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 177 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–177 of 177.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $28.7203/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238285991 CMS
Exelixis Inc. $19.9603/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218806723 CMS
Kedplasma LLC $5,000.0002/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202992308 CMS
Merck Sharp & Dohme LLC $29.6002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238192844 CMS
PharmaEssentia USA Corporation $19.3602/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246825262 CMS
ABBVIE INC. $15.3202/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201577616 CMS
Eisai Inc. $29.1002/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244516957 CMS
Genentech USA, Inc. $18.1102/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211602234 CMS
ADC THERAPEUTICS AMERICA, INC. $13.8002/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246125738 CMS
Janssen Biotech, Inc. $28.8902/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174785700 CMS
PharmaEssentia USA Corporation $23.9802/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246825258 CMS
Adaptive Biotechnologies Corporation $10.2002/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254941100 CMS
Kedplasma LLC $5,000.0001/31/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202992312 CMS
Incyte Corporation $16.2401/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226012487 CMS
Merck Sharp & Dohme LLC $26.2901/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238193186 CMS
AstraZeneca Pharmaceuticals LP $23.8301/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207300798 CMS
PFIZER INC. $15.8301/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231340678 CMS
Karyopharm Therapeutics Inc. $24.2201/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246652814 CMS
SOBI, INC $16.9801/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240223698 CMS
ABBVIE INC. $15.3901/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201577614 CMS
Celgene Corporation $31.1901/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184485694 CMS
Genentech USA, Inc. $20.1001/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211602241 CMS
SOBI, INC $15.3801/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240223702 CMS
BeiGene USA, Inc. $17.3901/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202880036 CMS
Celgene Corporation $25.2501/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184485692 CMS
Incyte Corporation $21.0301/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226012575 CMS
AstraZeneca Pharmaceuticals LP $21.8701/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206426159 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $49,831.38 187
PY2020 $23,224.53 48
PY2021 $20,292.09 76
PY2022 $65,082.50 206
PY2023 $55,932.67 194
PY2024 $82,017.49 180
PY2025 $69,512.79 177

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $372,436.74 37
PY2024 Principal investigator $646,164.27 48
PY2023 Principal investigator $111,029.00 31
PY2022 Principal investigator $104,696.00 27
PY2021 Principal investigator $77,836.00 26
PY2020 Principal investigator $29,040.00 15
PY2019 Principal investigator $353,397.48 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $14,399.00 12/08/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081605
Principal investigator 1 SANOFI US SERVICES INC. $17,747.00 11/10/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081771
Principal investigator 1 SANOFI US SERVICES INC. $21,555.50 11/10/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081775
Principal investigator 1 Janssen Research & Development, LLC $335.00 11/07/2025 Non-covered Recipient Entity
SPARTANBURG REGIONAL HEALTH SERVICE
A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175388586
Principal investigator 1 SANOFI US SERVICES INC. $4,750.00 10/27/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081739
Principal investigator 1 SANOFI US SERVICES INC. $13,630.00 10/06/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081731
Principal investigator 1 SANOFI US SERVICES INC. $16,547.00 09/15/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081718
Principal investigator 1 SANOFI US SERVICES INC. $14,399.00 09/15/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081722
Principal investigator 1 Janssen Research & Development, LLC $2,350.00 08/25/2025 Non-covered Recipient Entity
SPARTANBURG REGIONAL HEALTH SERVICE S DISTRICT INC
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175388556
Principal investigator 1 SANOFI US SERVICES INC. $8,398.02 08/11/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081711
Principal investigator 1 SANOFI US SERVICES INC. $13,630.00 08/11/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081714
Principal investigator 1 SANOFI US SERVICES INC. $2,055.00 08/04/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081703
Principal investigator 1 Karyopharm Therapeutics Inc. $50.00 07/09/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District, Inc.
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664868
Principal investigator 1 Janssen Research & Development, LLC $335.00 07/07/2025 Non-covered Recipient Entity
SPARTANBURG REGIONAL HEALTH SERVICE S DISTRICT INC
A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175388549
Principal investigator 1 SANOFI US SERVICES INC. $9,513.00 07/07/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081690
Principal investigator 1 Janssen Research & Development, LLC $2,350.00 06/30/2025 Non-covered Recipient Entity
SPARTANBURG REGIONAL HEALTH SERVICE S DISTRICT INC
A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175388579
Principal investigator 1 Celgene Corporation $57,822.00 06/27/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1222306469
Principal investigator 1 SANOFI US SERVICES INC. $14,399.00 06/09/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081677
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,506.12 05/27/2025 Non-covered Recipient Entity
Gibbs Cancer Center & Research Institute
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235997095
Principal investigator 1 Janssen Research & Development, LLC $390.00 05/09/2025 Non-covered Recipient Entity
SPARTANBURG REGIONAL HEALTH SERVICE S DISTRICT INC
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175388561
Principal investigator 1 Janssen Research & Development, LLC $335.00 05/05/2025 Non-covered Recipient Entity
SPARTANBURG REGIONAL HEALTH SERVICE S DISTRICT INC
A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175388593
Principal investigator 1 SANOFI US SERVICES INC. $15,547.00 05/05/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081654
Principal investigator 1 SANOFI US SERVICES INC. $17,015.00 05/05/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081658
Principal investigator 1 Janssen Research & Development, LLC $4,900.00 04/25/2025 Non-covered Recipient Entity
SPARTANBURG REGIONAL HEALTH SERVICE S DISTRICT INC
A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175388567
Principal investigator 1 SANOFI US SERVICES INC. $2,625.00 04/21/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081649
Principal investigator 1 SANOFI US SERVICES INC. $10,312.00 04/02/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081642
Principal investigator 1 Karyopharm Therapeutics Inc. $950.00 03/17/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District, Inc.
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664862
Principal investigator 1 Karyopharm Therapeutics Inc. $200.00 03/17/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District, Inc.
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664866
Principal investigator 1 SANOFI US SERVICES INC. $17,015.00 03/17/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081638
Principal investigator 1 SANOFI US SERVICES INC. $30,147.00 03/10/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081629
Principal investigator 1 Janssen Research & Development, LLC $390.00 03/06/2025 Non-covered Recipient Entity
SPARTANBURG REGIONAL HEALTH SERVICE S DISTRICT INC
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175388598
Principal investigator 1 SANOFI US SERVICES INC. $6,815.00 02/18/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081625
Principal investigator 1 Karyopharm Therapeutics Inc. $400.00 02/14/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District, Inc.
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664864
Principal investigator 1 Karyopharm Therapeutics Inc. $11,118.00 02/14/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District, Inc.
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664870
Principal investigator 1 Karyopharm Therapeutics Inc. $6,450.10 02/14/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District, Inc.
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664872
Principal investigator 1 SANOFI US SERVICES INC. $2,325.00 02/10/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081617
Principal investigator 1 SANOFI US SERVICES INC. $26,732.00 02/10/2025 Non-covered Recipient Entity
Spartanburg Regional Health Services District Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226081621